Correlations of soluble interleukin-2 and tumor necrosis factor type II receptors with immunologic and virologic responses under HAART

Journal of Clinical Immunology

Volumn 22, Issue 2, 2002, Pages 75-82

  Bonnet, F ^a   Saves M ^b   Morlat, Ph ^a   Droz, C ^b   Chene G ^b   Peuchant, E ^a   Bernard, N ^a   Lacoste, D ^a   Salamon, R ^b   Beylot, J ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

^b INSERM   (France)

Author keywords

HIV; Marker of immune activation; Protease inhibitor; Receptor; Soluble interleukin 2 receptor; Soluble tumor necrosis factor

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; INTERLEUKIN 2 RECEPTOR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TUMOR NECROSIS FACTOR RECEPTOR 2; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; VIRAL LOAD;

EID: 0036199089     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014475618504     Document Type: Article

References (24)

1. Monitoring plasma HIV-1 RNA levels in addition to CD4+lymphocyte count improves assessment of antiretroviral therapeutic response: ACTG Protocol Virology Substudy Team
2. Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection
3. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
4. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection
5. Prognostic value of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy
6. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements
7. Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease?
8. Soluble IL-2 receptor and tumor necrosis factor-alpha in plasma of haemophilia patients infected with HIV
9. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults
10. Effect of HAART on natural history of AIDS-related opportunistic disorders
11. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea
12. Protease inhibitor and triple-drug therapy: Cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment
13. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure
14. Interleukin-1 and tumor necrosis factor-Ã can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 by binding to the CD4 receptor
15. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state
16. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat
17. Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): Enhancement of HIV replication
18. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: A comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort study
19. The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro
20. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro
21. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
22. Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection
23. HIV-1-specific immune responses in subjects who temporaly contain virus replication after discontinuation of highly active antiretroviral therapy
24. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort study